Novo Nordisk A/S Stock News

Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to open an office in India this year to tap innovation and a growing healthcare market, its CEO Kasim Kutay

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

Novo Nordisk is one of the leading developers of weight-loss drugs. It just shared some great early-stage clinical trial data from one of its programs.

Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.

Next thing: weight loss funds in the works.

Building a stock investment portfolio isn't easy. One moment, you are tempted to wait for a dip, and another, you want to give in to the temptation of buying a stock at a premium with the hopes that i

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for a

Shares of Novo Nordisk recently rose to a new all-time high in response to clinical trial results for an experimental new weight-management drug named amycretin. Amycretin is a potential first-in-clas

Viking Therapeutics recently unveiled positive clinical trial results for its anti-obesity medication. The treatment is in phase 2 trials, but its results suggest it could rival other weight loss drug

Investors' eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

'Mad Money' host Jim Cramer looks at Europe's top performing stocks, deemed the 'Super 7'.